8 September - 11 September 2019

20th SCI/RSC Medicinal Chemistry Symposium

Organised by:

 SCI's Fine Chemicals Group and RSC's Biological & Medicinal Chemistry Sector

Cambridge, UK

Join this event now

Prices start from £200.00

The organisers invite you to the 20th SCI / RSC Medicinal Chemistry Symposium, Europe’s premier biennial Medicinal Chemistry event, focussing on first disclosures and new strategies in Medicinal Chemistry.


This conference will be of interest to both academic and industrial scientists engaged in all aspects of the drug discovery and development process. 



Sunday 8 September 2019

13.30 Medicinal chemistry workshop (signed-up early-career delegates only)
15.00 Registration and refreshments
18.30 Welcome BBQ 

Monday 9 September 2019

08.50 Welcome and opening remarks
Nadia Ahmad, Vertex UK, Chair, Organising Committee
09.00 Novel potent and selective 5HT2C receptor agonists for the treatment of neurological disorders
Lynette Smyth, AbbVie, Germany
09.40 Context dependent inhibition or rescue of MALT1 protease with the same allosteric binder
Jean Quancard, Novartis Institutes for BioMedical Research, Switzerland
10.10 Covalent fragment discovery unlocks an intractable protein-protein interaction
Ed Tate, Imperial College London, UK
10.40   Refreshments and exhibitors
11.10 The discovery of the selective orexin 1 receptor antagonist (SO- 1RA) ACT-539313 for the treatment of anxiety disorders
Jodi Williams, Idorsia Pharmaceuticals, Switzerland
11.50 Discovery of JNJ-61393215, a Selective Orexin-1 Receptor Antagonist
Brock T. Shireman, Janssen Research & Development, USA
12.20 Ventures in new target space: drugging the DUBs
Tim Harrison, ALMAC, UK
12.50 Malcolm Campbell Memorial Prize presentation
13.05 Lunch
14.15 The investigation of small molecule inhibitors of PLD for the treatment of ALS
Tricia May-Dracka, Biogen, USA
14.55 Imaging mutant Huntingtin aggregates:  development of PET clinical candidates for Huntington’s disease
Michael Prime, Evotec, UK
15.25 Optimising molecular design
Nathan Brown, BenevolentAI, UK
15.55 Refreshments and exhibitors
16.25 Flash poster presentations
16.50   Do we need to change the definition of drug like properties?
Mike Schultz, Novartis Institutes for Biomedical Research, USA
17.20   Rules are for the obedience of fools and guidance of the wise – an objective appraisal of best practices in medicinal chemistry over 40 years
Rob Young, GlaxoSmithKline, UK
17.50   Poster session and reception
19.30   College Dinner


Tuesday 10 September 2019

09.10 Apelin: a multi-faceted GPCR and a target for the treatment of glioblastoma and pulmonary arterial hypertension
Robert Glen, Cambridge University, UK
09.40 Reactive (Cys-targeting) fragment libraries
David House, GlaxoSmithkline, UK
10.10 Refreshments and exhibitors
10.40 TLR8 agonist: discovery of GS-9688, a selective toll-like receptor 8 agonist for the treatment of HBV
Richard Mackman, Gilead Sciences, USA
11.10 Harnessing Hippo: targeting the TEAD transcription factors in cancer
James Crawford, Genentech, USA
11.40 Discovery of PF-06882961: A potent, orally bioavailable small molecule agonist of the GLP-1 receptor
David Edmonds, Pfizer, USA
12.20 Lunch
13.30 Discovery and development of novel amidobenzimidazole (ABZI) STING agonists as cancer therapeutics
Joshi Ramanjulu, GlaxoSmithKline, USA
14.10 The discovery of Cenerimod – A selective S1P1 receptor modulator in phase II clinical trials in SLE
Martin Bolli, Idorsia Pharmaceuticals, Switzerland
14.40 Refreshments and exhibitors
15.10 Complex-selective HDAC inhibitors promote synaptic resilience for therapeutic treatment of synaptopathies
Nathan Fuller, Rodin Therapeutics, USA
15.40 The discovery of Kisqali® (ribociclib), a CDK4/6 inhibitor for the treatment of breast cancer
Chris Brain/Steven Howard, Novartis Institutes for Biomedical Research, USA /Astex Pharmaceuticals, UK
16.20 Flash poster presentations
16.45 Poster session II and refreshments
18.45 Walk to St John’s College
19.00 Drinks reception
19.45 Gala dinner at St John’s College


Wednesday 11 September 2019

09.00 Discovery of BAY 2402234 by phenotypic screening: A human Dihydroorotate Dehydrogenase (DHODH) inhibitor in clinical trials for the treatment of myeloid malignancies
Stefan Gradl, Bayer, Germany
09.40   Allosteric covalent inhibitors of the mutant GTPase KRASG12C
Jason Kettle, AstraZeneca, UK
10.10   The challenges of drug discovery in Chagas disease
Silvia Gonzalez-del Valle, GlaxoSmithKline, Spain
10.40   Refreshments and exhibitors
11.10   Discovery of LY3154207, a potent and selective dopamine receptor D1 positive allosteric modulator for the treatment of Parkinson’s disease dementia
Junliang Hao, Lilly Research Laboratories, USA
11.50   Discovery of pre-clinical candidate Calcitonin Gene- Related Peptide (CGRP) receptor antagonist HTL0022562 and an innovative new class of CGRP ligands
John Christopher, Sosei-Heptares, UK
12.30   Lunch
13.40   Validation of a novel CNS target directly in humans: A case study
Patrick Schnider, Roche, Switzerland
14.20   Discovery of novel positive allosteric modulators of the alpha 7 nicotinic acetylcholine receptor for the treatment of cognitive disorders
Ian Bell, Merck, USA
14.50   Discovery of AZD7648, a potent and selective DNA-PK inhibitor
Frederick W. Goldberg, AstraZeneca, UK
15:30   Closing remarks


Approaches to Synthesis and Scale-up of a Wee-1 Kinase Inhibitor
Dr Thomas Langer, AstraZeneca, UK

Approaches to Synthesis and Scale-up of a Wee-1 Kinase Inhibitor
Dr Thomas Langer, AstraZeneca, UK

Novel industrial applications for electrochemistry - expecting the unexpected
Dr Patrik Stenner, Evonik, Germany

Novel industrial applications for electrochemistry - expecting the unexpected
Dr Patrik Stenner, Evonik, Germany

Novel industrial applications for electrochemistry - expecting the unexpected
Dr Patrik Stenner, Evonik, Germany

Novel industrial applications for electrochemistry - expecting the unexpected
Dr Patrik Stenner, Evonik, Germany

Novel industrial applications for electrochemistry - expecting the unexpected
Dr Patrik Stenner, Evonik, Germany

Venue and Contact


Storey’s Way

Conference Team

Tel: +44 (0)20 7598 1561

Email: conferences@soci.org


Registration fees

£400 SCI / RSC Member
£200 SCI / RSC Student Member
£280 SCI / RSC Subsidised Member
£500 Non-Member


Accommodation packages

£375 Single room, shared bathroom
£430 Single room, ensuite bathroom
£480 Superior single room, ensuite bathroom

Accommodation packages include three nights' bed and breakfast (Sunday - Tuesday) and the three dinners listed below

Accommodation at the college is limited and will be sold on a first-come-first-served basis


Dinners (for non-residents only)

£30 BBQ, Sunday evening
£50 Conference dinner, Monday evening

Become SCI Member and save on this and future events

See Membership Options

You must sign up for membership to join this event. FREE membership options available.

Contributions from the whole field of medicinal chemistry are invited.  Flash presentation sessions are planned which will involve a two-minute presentation of poster highlights. Please submit A4 abstracts of your poster presentation to daisy.goddard@soci.org and indicate whether or not you would like to be included for consideration in the flash presentation session. The final deadine for submission of posters is Wednesday 1 May.



Exhibition and Sponsorship
An exhibition will take place alongside the conference during refreshment breaks for companies and related organisations who may wish to exhibit. Spaces are limited and will be allocated on a first come, first served basis. For further information please email daisy.goddard@soci.org

Become an SCI Member to receive events discounts

Join SCI